{"name":"Collegium Medicum w Bydgoszczy","slug":"collegium-medicum-w-bydgoszczy","ticker":"","exchange":"","domain":"cm.umk.pl","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Ticagrelor followed with Methoxyflurane","genericName":"Ticagrelor followed with Methoxyflurane","slug":"ticagrelor-followed-with-methoxyflurane","indication":"Acute pain relief in patients receiving ticagrelor for cardiovascular indications","status":"marketed"},{"name":"Crushed ticagrelor followed by morphine","genericName":"Crushed ticagrelor followed by morphine","slug":"crushed-ticagrelor-followed-by-morphine","indication":"Acute coronary syndrome with rapid antiplatelet and analgesic management","status":"marketed"},{"name":"Crushed ticagrelor, morphine,metoclopramide","genericName":"Crushed ticagrelor, morphine,metoclopramide","slug":"crushed-ticagrelor-morphine-metoclopramide","indication":"Acute coronary syndrome with associated pain and nausea","status":"marketed"},{"name":"Crushed ticagrelor, morphine,naloxone","genericName":"Crushed ticagrelor, morphine,naloxone","slug":"crushed-ticagrelor-morphine-naloxone","indication":"Acute coronary syndrome with pain management","status":"marketed"},{"name":"Integral ticagrelor","genericName":"Integral ticagrelor","slug":"integral-ticagrelor","indication":"Acute coronary syndrome (ACS)","status":"marketed"},{"name":"Ticagrelor followed with Morphine","genericName":"Ticagrelor followed with Morphine","slug":"ticagrelor-followed-with-morphine","indication":"Acute coronary syndrome (STEMI/NSTEMI) with pain management","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Flozin","genericName":"Flozin","slug":"flozin","indication":"Other","status":"phase_2"},{"name":"Pulverized ticagrelor orally","genericName":"Pulverized ticagrelor orally","slug":"pulverized-ticagrelor-orally","indication":"Other","status":"marketed"},{"name":"Pulverized ticagrelor sublingually","genericName":"Pulverized ticagrelor sublingually","slug":"pulverized-ticagrelor-sublingually","indication":"Other","status":"marketed"},{"name":"Rosuvastatin and Ezetimibe morning or evening administration","genericName":"Rosuvastatin and Ezetimibe morning or evening administration","slug":"rosuvastatin-and-ezetimibe-morning-or-evening-administration","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Ticagrelor followed with Methoxyflurane","genericName":"Ticagrelor followed with Methoxyflurane","slug":"ticagrelor-followed-with-methoxyflurane","phase":"marketed","mechanism":"Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms.","indications":["Acute pain relief in patients receiving ticagrelor for cardiovascular indications","Breakthrough pain management in acute coronary syndrome or other thrombotic conditions"],"catalyst":""},{"name":"Crushed ticagrelor followed by morphine","genericName":"Crushed ticagrelor followed by morphine","slug":"crushed-ticagrelor-followed-by-morphine","phase":"marketed","mechanism":"Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis.","indications":["Acute coronary syndrome with rapid antiplatelet and analgesic management","Acute myocardial infarction with pain control"],"catalyst":""},{"name":"Crushed ticagrelor, morphine,metoclopramide","genericName":"Crushed ticagrelor, morphine,metoclopramide","slug":"crushed-ticagrelor-morphine-metoclopramide","phase":"marketed","mechanism":"This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and metoclopramide to enhance gastric motility and reduce nausea.","indications":["Acute coronary syndrome with associated pain and nausea"],"catalyst":""},{"name":"Crushed ticagrelor, morphine,naloxone","genericName":"Crushed ticagrelor, morphine,naloxone","slug":"crushed-ticagrelor-morphine-naloxone","phase":"marketed","mechanism":"This combination uses ticagrelor to inhibit platelet aggregation, morphine for pain relief and anxiolysis, and naloxone as an opioid antagonist to reduce morphine-related adverse effects.","indications":["Acute coronary syndrome with pain management","Post-acute cardiac event analgesia"],"catalyst":""},{"name":"Flozin","genericName":"Flozin","slug":"flozin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Integral ticagrelor","genericName":"Integral ticagrelor","slug":"integral-ticagrelor","phase":"marketed","mechanism":"Ticagrelor is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.","indications":["Acute coronary syndrome (ACS)","Secondary prevention of thrombotic cardiovascular events"],"catalyst":""},{"name":"Pulverized ticagrelor orally","genericName":"Pulverized ticagrelor orally","slug":"pulverized-ticagrelor-orally","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pulverized ticagrelor sublingually","genericName":"Pulverized ticagrelor sublingually","slug":"pulverized-ticagrelor-sublingually","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rosuvastatin and Ezetimibe morning or evening administration","genericName":"Rosuvastatin and Ezetimibe morning or evening administration","slug":"rosuvastatin-and-ezetimibe-morning-or-evening-administration","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ticagrelor followed with Morphine","genericName":"Ticagrelor followed with Morphine","slug":"ticagrelor-followed-with-morphine","phase":"marketed","mechanism":"Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while morphine provides opioid analgesia; together they are used in acute coronary syndrome to prevent thrombotic events and manage pain.","indications":["Acute coronary syndrome (STEMI/NSTEMI) with pain management"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE02eW1JUE9yUklEWG1wOTNJWUYySE5SZXNOTUZfTFNoLWdDZ0kzbHRONnhfalJqN09Xd3RXVjJLT2FjMTA4Z2JjZzRLYmhyLWQxa09QbGpacFlBWVVrT3cxVEM3NnE4YjVuY2c?oc=5","date":"2026-01-17","type":"pipeline","source":"ACS Publications","summary":"Culture Dimensionality Modulates Gallium Maltolate Response in Glioblastoma: Comparative Analyses in 2D and 3D Models - ACS Publications","headline":"Culture Dimensionality Modulates Gallium Maltolate Response in Glioblastoma: Comparative Analyses in 2D and 3D Models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBRdmRhNGktdTRrSmJpcTlUbkU5d2x6RmpzRkYyNzlUR29QTTJzSkREU3BibVJBVHJTa1BWTzJnQkc1SFc2c3YtelVIZkZ2Rk1zeGd5UFVVckpoVE9GbDNN?oc=5","date":"2024-06-25","type":"trial","source":"Nature","summary":"Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study - Nature","headline":"Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the r","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQM1hzWmFoaHozZm9WdzFNb3pTT0xLQkNjWVJwaXdDc015cnM3a1FBZTF0MmdNSnBnc1FlTVBLRFFWOHdoNlNOM2FuZnQwcl9qckpWWmlRVE0yNWd5eHpGazVrRGs3d1FVVEtlVlIweThYVmhOMlMxV0tGMlBFMFl6XzlmS2RTVmtkSHhoT2tab05KcjdzUG9PdUpSS3hJVEE?oc=5","date":"2023-08-01","type":"pipeline","source":"Via Medica Journals","summary":"Serum amino acid profiling in differentiating clinical outcomes of multiple sclerosis - Via Medica Journals","headline":"Serum amino acid profiling in differentiating clinical outcomes of multiple sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNb0VGYkxqUUpRc0FHd24yd2hmclpKZGRWS2RDSzFXU05TTHdGNWw0NkY2MDlDTDQ1emVxenBiM3J6ZXkzXzktcGNOMlJLUERyR1NvZ1hDTkNlUE9lSklfNVh2MjRTemNvTkpyd010NThjM1RqcnhnUGJlaHlzUmlpSU9ZQ2tRTnNYY21sc3pYaDhNMndOdXFhdEVjZEdaQXc?oc=5","date":"2023-07-07","type":"trial","source":"Via Medica Journals","summary":"Does ASTRAL score at hospital admission predict symptomatic haemorrhagic transformation in acute ischaemic stroke after revascularisation? A pilot single-centre study | Świtońska | Neurologia i Neuroc","headline":"Does ASTRAL score at hospital admission predict symptomatic haemorrhagic transformation in acute ischaemic stroke after ","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQQWxPU0haak14THRTSlZ6SmVXaWNDa0tzajJpckF4aTVZdDdTa3p6cmZaS3JQWTRkZTJVSG5xYTV2cko1QktpbFgzVmpWamZ6OTNocjV6U0FNTWdicW15WjV4RjFkdExpQVFPSWFrQ0xydmhUU2puOE9PWkQ3TkJKUXZENHFVMUpxX3VpZFk3NWk0YnJyaXc?oc=5","date":"2022-06-06","type":"regulatory","source":"Via Medica Journals","summary":"Vaccinations following CAR-T cell therapy: summary of reported cases and state-of-the-art review of current recommendations | Styczyński | Acta Haematologica Polonica - Via Medica Journals","headline":"Vaccinations following CAR-T cell therapy: summary of reported cases and state-of-the-art review of current recommendati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQWGljRG5LWjFPS0dib09jMnBITTdaOWpPcXFhMjFIWHdnbG12cWNlS0Nvd2RaSThnR2Ytdk9lVGhKektkTzB3bTlJNFJ6MTdjVGlBWk9iNk1yNEp5V2V1S0t2UDRILTNzVW9mOWVfLVNXZ2RlT2ZpOG9XcHBzeHhVMEJleXgtQ2NLZ0FZ?oc=5","date":"2016-09-09","type":"pipeline","source":"Via Medica Journals","summary":"The role of the pharmacist in the care of patients with cardiovascular diseases - Via Medica Journals","headline":"The role of the pharmacist in the care of patients with cardiovascular diseases","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"marketed":9,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}